October 11th 2023

DisCoVery publishes an article on association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients

The role of antiviral treatment in COVID-19 hospitalized patients remains controversial. In this study, we analyzed nasopharyngeal viral load and the clinical score of patients (as measured by the National Early Warning Score 2 (NEWS-2)) in the DisCoVeRy trial, where 664 patients were randomized to either standard of care (SoC) or SoC + remdesivir. We [...]
Read more
September 15th 2023

EU-RESPONSE supports a global meta-analysis on JAK inhibitors in hospitalized COVID-19 patients

Several trial consortia, including EU RESPONSE, have investigated JAK inhibitors (such as baricitinib, ruxolitinib, and tofacitinib) for the treatment in patients hospitalized with COVID-19. However, these trials showed conflicting results, especially regarding specific subgroup of patients such as patients with co-morbidities. As part of EU RESPONSE’s effort to generate high-quality evidence for COVID-19 treatments, we [...]
Read more
June 15th 2023

DisCoVery publishes an article on quality control in the context of the SARS-CoV 2 epidemic

Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20–15 DisCoVeRy study The study Sponsor is responsible for ensuring participants’ safety and reliability of the data collected, in particular through the monitoring carried out in the investigating centers. This article presents the experience of quality control assurance in [...]
Read more
June 5th 2023

DisCoVery publishes an article on management of pharmacovigilance during the COVID-19 pandemic crisis

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial During a pandemic crisis, sponsors should educate and train investigators about the importance of the pharmacovigilance issues. •The assessment of the safety profile of the investigational medicinal drug is [...]
Read more
May 15th 2023

EU-RESPONSE first face-to-face consortium meeting

EU-RESPONSE first face-to-face consortium meeting was succesfully held in Oslo on 11-12 May 2023, in presence of the chair of EU-RESPONSE Scientific and Ethics Advisory Board and other invited external experts. Around 60 people attended in person to discuss the project progress, acheivements and next steps.
Read more
January 13th 2023

EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients

EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients The first drug tested on EU-SolidAct is baricitinib, a tablet approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, have been published in Critical Care on January 10th [...]
Read more
March 7th 2022

EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial 

EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial  Based on recent results from the Recovery trial showing a mortality benefit for baricitinib in severe COVID-19, EU SolidAct has decided to stop inclusion of immunocompetent participants to the baricitinib trial. However, as the safety and benefit of immunomodulators including baricitinib is still not [...]
Read more
March 2nd 2022

remdesivir has a significant antiviral activity, reducing the amount of viral particles released by infected cells

An article published on 2 March in The Journal of Antimicrobial Chemotherapy, shows the effect of remdesivir on viral dynamics in COVID-19 hospitalized patients.  The use of remdesivir has been associated to contradictory virological and clinical results in the past months. Here, we analyzed its effect on viral dynamics in the DisCoVeRy trial, where 665 [...]
Read more
January 27th 2022

BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients

Bergen, Norway and Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients.   The EU-SolidAct trial - European [...]
Read more
September 24th 2021

Remdesivir Ineffective in Patients Hospitalized With COVID-19 and the DisCoVeRy Trial Continues with a New Antiviral

The Discovery clinical trial was initially launched in France by Inserm in March 2020, to evaluate several possible treatments for COVID-19. Its European expansion was made possible by the EU-RESPONSE[1] project, funded by Europe. Interim analysis of the trial data had led to the recommendation to suspend the recruitment of remdesivir group patients for futility [...]
Read more
June 28th 2021

Launch of European Covid-19 trials coordination module website

Launch of European Covid-19 trials coordination module website. The coordination module of the EU-funded projects RECOVER1 and EU-RESPONSE2 has launched its website It centralises information for academics and industry on access to the three large Pan-European adaptive platform trials currently underway: DisCoVeRy, EU-SolidAct & REMAP-CAP. A coordinated Pan-European approach is essential for tackling the [...]
Read more
May 28th 2021

EU SolidAct – a pan-European platform for pandemic research and preparedness

EU SolidAct - a pan-European platform for pandemic research and preparedness There is an urgent need for rapid and coordinated investigation of new candidate drugs during pandemics. EU-SolidAct is an Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with COVID-19 and to facilitate a joint European response to future pandemics. The first [...]
Read more
April 29th 2021

Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial

April 29, 2021 – A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19. It is planned to enroll 1240 patients across Europe in this Phase III clinical trial. With its wealth of experience in the domain of targeted therapies [...]
Read more
October 20th 2020

Launch of the EU-RESPONSE project

The EU-RESPONSE Kick-off meeting took place on October 20th 2020 via videoconference. This meeting gathered the whole EU-RESPONSE consortium to present and discuss the planned work programme with the participation of European Commission representatives and external invitees.
Read more
July 1st 2020

DisCoVeRy trial in practice

The DisCoVeRy clinical trial is an adaptive, randomized, open-label clinical trial, add-on of the Solidarity trial, that aims to evaluate the safety and efficacy of four antiviral therapeutic strategies as compared with standard of care. Patients are hospitalized in conventional departments or intensive care units both from academic or non-academic hospitals throughout Europe with COVID-19 [...]
Read more